The FDA approved tofacitinib (Xeljanz, Xeljanz XR) for treating active ankylosing spondylitis in adults, Pfizer announced on Tuesday.
Dr. John Cush RheumNow
4 years 9 months ago
New podcast up!
Drs. Jack Cush and Martin Bergman review the topic of treat-to-target (T2T) management in rheumatology.
Both will debate the pro's and con's of the T2T strategy at the upcoming RWCS meeting on Feb. 17, 2022.
https://t.co/TBX2RvCCB6 https://t.co/LYBoViqmpD
The FDA has approved upadacitinib (Rinvoq) today for use in the treatment of adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.
Safety analysis of over 1000 adverse events associated with the use of tocilizumab in the treatment of COVID‐19 infection shows both rare expected and some unexpected AE.
Dr. John Cush RheumNow
4 years 9 months ago
Reproductive Health in Rheumatic Diseases: Drs. Bermas, Buyon and Dao
https://t.co/mnRwCOGYXp https://t.co/j8xSm60jLr
Dr. John Cush RheumNow
4 years 9 months ago
Increased risk death in 310 scleroderma pts: 63 diffuse SSc, 279 limited dz & 33 sine scleroderma (SMR = 1.88). Reduced survival at 10 yrs (78%) & 15 yrs(61%). 69 deaths, 46% in diffuse PSS - due to ILD, PHA, and GI involvement https://t.co/w300etSls2
The numbers on treatment adherence is disappointingly low in RA, with a number of psychological, communication and logistical factors that outweigh the potentially negative influence of sociodemographic or clinical factors.
A 6-month prospective cohort study of RA patients assessed drug adherence; with one-third each falling into the following treatment groups:
Systemic onset juvenile idiopathic arthritis (sJIA) is a dramatic onset inflammatory condition marked by spiking fevers, intermittent rash, polyarthritis and a host of other hyperinflammatory manifestations.
Dr. John Cush RheumNow
4 years 9 months ago
NYC Hosp for Special Surgery is the 1st to use a "smart" knee arthroplasty - TKR with a smart sensor capable of monitoring steps, speed, range of motion & other knee functions fed back to the orthopedist = called Persona IQ, FDA authorized https://t.co/QR49JC7oCz
Dr. John Cush RheumNow
4 years 9 months ago
Pre-clinical RA: starting off the wrong foot
https://t.co/LA2dLaAM6C https://t.co/lgKFY0zDeq
Dr. John Cush RheumNow
4 years 9 months ago
Genes and Obesity Tied to Higher Gout Risk in Women
Excess adiposity and genetic predisposition both contributed to risk of gout among U.S. women, with the risks being highest when both factors are present, a large prospective study found.
https://t.co/vLR8GJC9qf https://t.co/6Scc5c0dUU
Dr. John Cush RheumNow
4 years 9 months ago
Fibromyalgia pts are prone to suicidal ideation (29.6%; OR 9.1), attempts (5.7%; OR 3.1), & events (OR 1.38), but significance lost when correcting for psych illness. Risk assoc w/ work, dz severity, obesity, addiction, chronic pain & co-morbidities. https://t.co/jjiZ5iZBjP https://t.co/cuCsKKcOj7
Dr. John Cush RheumNow
4 years 9 months ago
ICYMI: TNF inhibitors and radiographic progression in axSpA
A remaining challenge for clinicians is the ability to delay, if not completely stop, structural progression in patients with (ax-Spa, whether they are diagnosed with -axSpa or nr-axSpA disease.
https://t.co/H0Fr54PwOP https://t.co/tFZJUr1j4B
Dr. John Cush RheumNow
4 years 9 months ago
ICYMI:CDC and the ICD-10 Coordination and Maintenance Committee has assigned a diagnostic code for non-radiographic axial spondyloarthritis (nr-axSpA) == M45.A
